Reason for request
Inclusion
Clinical Benefit
| Substantial |
Substantial actual benefit |
Clinical Added Value
| important |
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation. |
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
KGHPT2FuMQQxAwGK
